Innovative Therapies in Neurodegeneration: Disease Modification & Regeneration

Neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis, are characterized by progressive neuronal loss, chronic neuroinflammation, and limited intrinsic regenerative capacity. Contemporary therapeutic strategies are increasingly shifting toward integrative frameworks that combine disease modification with regenerative and immunomodulatory approaches. Among these, mesenchymal stem cells (MSCs) and cord blood–derived stem and progenitor cells have emerged as clinically translatable platforms with demonstrated safety and early signals of efficacy across multiple early-phase trials.

MSCs exert pleiotropic therapeutic effects through secretion of neurotrophic factors, anti-inflammatory cytokines, and extracellular vesicles, thereby promoting neuronal survival, enhancing synaptic plasticity, and modulating the neuroimmune microenvironment. These cells also exhibit anti-apoptotic and antioxidative properties, directly targeting key pathological mechanisms underlying neurodegeneration. Cord blood–derived cells, including hematopoietic and endothelial progenitors, further contribute to neurovascular repair and immune regulation, with increasing evidence supporting their role in stimulating endogenous regeneration.

Advances in tissue culture technologies—including large-scale expansion, hypoxic preconditioning, and functional priming—have significantly improved the therapeutic consistency, homing efficiency, and survival of transplanted cells. Recent systematic analyses indicate that over 90 clinical trials have evaluated stem cell–based therapies in neurodegenerative disorders, with phase I/II studies demonstrating safety, feasibility, and preliminary efficacy signals such as improved functional scores and reduced neuroinflammatory markers. Notably, ongoing clinical trials using umbilical cord–derived MSCs in Parkinson’s disease and intracerebral delivery approaches highlight continued translational momentum.

A critical mechanistic axis underlying these therapies is the dynamic cross-talk between transplanted stem cells and resident immune populations, particularly microglia, enabling a shift toward neuroprotective phenotypes and enhanced clearance of pathological protein aggregates. Emerging strategies further exploit stem cell–derived secretomes and exosomes as cell-free therapeutics, offering reduced immunogenicity while retaining regenerative and immunomodulatory functions. Additionally, early-phase clinical trials involving intracerebroventricular administration of cord blood–derived MSCs in Alzheimer’s disease have demonstrated feasibility and safety, supporting their translational relevance.

Despite encouraging progress, key challenges—including cellular heterogeneity, scalability, immune compatibility, and durability of response—remain to be addressed. Integrating tissue culture–driven optimization with combinatorial approaches that couple stem cell–mediated regeneration, immune modulation, and targeted molecular therapies may provide a robust and scalable pathway toward durable disease modification in neurodegenerative disorders.